Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2018 | Research

Role of perfusion parameters on DCE-MRI and ADC values on DWMRI for invasive ductal carcinoma at 3.0 Tesla

Authors: Fei Liu, Mei Wang, Haige Li

Published in: World Journal of Surgical Oncology | Issue 1/2018

Abstract

Background

The value of apparent diffusion coefficient (ADC) values and quantitative parameters (Ktrans, Kep, Ve) in detecting prognostic factor at 3.0 Tesla remains unclear, especially in predicting prognosis of breast cancer.

Methods

A total of 151 patients with IDC underwent breast DCE-MRI and DWI-MRI at 3.0 Tesla following surgery. The ADC values were acquired with b values of 0 and 1000 s/mm². The relationship between ADC values or DCE-MRI quantitative parameters and size, histologic grade (HG), lymph node metastasis (LNM), ER, PR, and Ki67 was evaluated. The predictive values of ADC, Ktrans, Kep, and Ve to prognosis of IDC were assessed.

Results

ADC value was positively related to size (P = 0.04) and HER2 (P = 0.046) expression and negatively related to ER (P = 0.012) and PR (P < 0.001) expression. Ktrans value has positive correlation with size (P < 0.001), HG (P < 0.001), LNM (P < 0.001), HER2 (P = 0.007), and Ki67 (P < 0.001) expression and negative correlation with ER (P < 0.001) and PR (P < 0.001) expression. Kep value was positively related to size (P < 0.001) and negatively related to ER (P < 0.001) and PR (P < 0.001) expression. Ve value was negatively related to HER2 expression (P = 0.004). The Cox hazard ratio (HR) of ADC, Ktrans, Kep, and Ve values on survival was 5.26 (P = 0.093), 1.081 (P = 0.002), 1.006 (P = 0.941), and 0.883 (P = 0.926), respectively.

Conclusions

Ktrans value was a best predictive indicator of HG, LNM, ER, PR, and Ki67 expression, and ADC value was the best predictive indicator of HER2. Preoperative use of the 3.0 Tesla could provide important information to determine the optimal treatment plan.

Akasbi Y, Bennis S, Abbass F, Znati K, Joutei KA, Amarti A, et al. Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez). BMC Res Notes. 2011;4(1):1–6.CrossRef

Blanchard A, Shiu R, Booth S, Sorensen G, Decorby N, Nistor A, et al. Gene expression profiling of early involuting mammary gland reveals novel genes potentially relevant to human breast cancer. Front Biosci. 2007;12(6):2221–32.PubMedCrossRef

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601.PubMedCrossRef

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273.PubMedCrossRef

Kapoor P, Prasad SVAV, editors. Image processing for early diagnosis of breast cancer using infrared images. The 2nd International Conference on Computer and Automation Engineering (ICCAE). 2010; pp. 564–566.

Egeland TA, Simonsen TG, Gaustad JV, Gulliksrud K, Ellingsen C, Rofstad EK. Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images. Radiat Res. 2009;172(3):339–47.PubMedCrossRef

Franiel T, Hamm B, Hricak H. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol. 2011;21(3):616–26.PubMedCrossRef

Donaldson SB, Bonington SC, Kershaw LE, Cowan R, Lyons J, Elliott T, et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol. 2013;82(12):2161–8.PubMedCrossRef

Montemurro F, Russo F, Martincich L, Cirillo S, Gatti M, Aglietta M, et al. Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. Acta Radiol. 2004;45(1):71–4.PubMedCrossRef

10.

Morrow M. Magnetic resonance imaging for screening, diagnosis, and eligibility for breast-conserving surgery: promises and pitfalls. Surg Oncol Clin N Am. 2010;19(3):475–92.PubMedCrossRef

11.

Schnapauff D, Zeile M, Niederhagen MB, Fleige B, Tunn PU, Hamm B, et al. Diffusion-weighted echo-planar magnetic resonance imaging for the assessment of tumor cellularity in patients with soft-tissue sarcomas. J Magn Reson Imaging. 2009;29(6):1355.PubMedCrossRef

12.

Barchetti F, Panebianco V. Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. Biomed Res Int. 2014;2014(1):316272.PubMedPubMedCentral

13.

Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60(1):125–30.PubMedCrossRef

14.

Tatsumi Y, Tanigawa N, Nishimura H, Nomura E, Mabuchi H, Matsuki M, et al. Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10. Gastric Cancer. 2006;9(2):120–8.PubMedCrossRef

15.

Orguc S, Basara I, Coskun T. Diffusion-weighted MR imaging of the breast: comparison of apparent diffusion coefficient values of normal breast tissue with benign and malignant breast lesions. Singap Med J. 2012;53(11):737–43.

16.

Razek AA, Gaballa G, Denewer A, Nada N. Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed. 2010;23(6):619–23.PubMedCrossRef

17.

Park SH, Choi HY, Hahn SY. Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion-weighted MRI at 3.0 Tesla. J Magn Reson Imaging. 2015;41(1):175–82.PubMedCrossRef

18.

Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223–32.PubMedCrossRef

19.

Turetschek K, Floyd E, Helbich T, Roberts TP, Shames DM, Wendland MF, et al. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. J Magn Reson Imaging. 2001;14(3):237.PubMedCrossRef

20.

Abramson RG, Arlinghaus LR, Weis JA, Li X, Dula AN, Chekmenev EY, et al. Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. Breast Cancer Targets Ther. 2012;2012(4):139.CrossRef

21.

Zhang L, Tang M, Min Z, Lu J, Lei X, Zhang X. Accuracy of combined dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging for breast cancer detection: a meta-analysis. Acta radiologica (Stockholm, Sweden : 1987). 2015;57(6):3264.

22.

Aribal E, Asadov R, Ramazan A, Ugurlu MÜ, Kaya H. Multiparametric breast MRI with 3T: effectivity of combination of contrast enhanced MRI, DWI and 1H single voxel spectroscopy in differentiation of Breast tumors. Eur J Radiol. 2016;85(5):979.PubMedCrossRef

23.

Koo HR, Cho N, Song IC, Kim H, Chang JM, Yi A, et al. Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers. J Magn Reson Imaging. 2012;36(1):145–51.PubMedCrossRef

24.

Bahri S, Chen JH, Yu HJ, Kuzucan A, Nalcioglu O, Su MY. Can dynamic contrast-enhanced MRI (DCE-MRI) predict tumor recurrence and lymph node status in patients with breast cancer? Ann Oncol. 2008;19(4):822.PubMedPubMedCentralCrossRef

25.

Avcu S, Arslan H, Unal O, Kotan C, Izmirli M. The role of diffusion-weighted MR imaging and ADC values in the diagnosis of gastric tumors. JBR-BTR. 2012;95(1):1–5.

26.

Pereira FP, Martins G, Carvalhaes dORV. Diffusion magnetic resonance imaging of the breast. Magn Reson Imaging Clin North Am. 2011;19(1):95.CrossRef

27.

Budde MD, Frank JA. Neurite beading is sufficient to decrease the apparent diffusion coefficient after ischemic stroke. Proc Natl Acad Sci. 2010;107(32):14472–7.PubMedCrossRef

28.

Cui XY, Chen HW. Role of diffusion-weighted magnetic resonance imaging in the diagnosis of extrahepatic cholangiocarcinoma. World J Gastroenterol. 2010;16(25):3196.PubMedPubMedCentralCrossRef

29.

Partridge SC, McDonald ES. Diffusion weighted magnetic resonance imaging of the breast: protocol optimization, interpretation, and clinical applications. Magn Reson Imaging Clin N Am. 2013;21(3):601–24.PubMedPubMedCentralCrossRef

30.

Boulogianni G, Chryssogonidis I, Drevelegas A. Diffusion weighted MRI and spectroscopy in invasive carcinoma of the breast at 3Tesla. Correlation with dynamic contrast enhancement and pathologic findings. Hippokratia. 2016;20(3):192–7.PubMedPubMedCentral

31.

Yoshito T, Ayako TT, Keigo E. Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T. J Magn Reson Imaging. 2010;30(2):249–55.

32.

Chen X, Li WL, Zhang YL, Wu Q, Guo YM, Bai ZL. Meta-analysis of quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesions. BMC Cancer. 2010;10(1):693.PubMedPubMedCentralCrossRef

33.

Fidalgo F, Rodrigues TC, Pinilla M, Silva AG, Maciel MS, Rosenberg C, et al. Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast. Tumor Biol. 2015;36(3):1835–48.CrossRef

34.

Li L, Wang K, Sun X, Wang K, Sun Y, Zhang G, et al. Parameters of dynamic contrast-enhanced MRI as imaging markers for angiogenesis and proliferation in human breast cancer. Med Sci Monit. 2015;21(2):376–82.PubMedPubMedCentral

35.

Han M, Kim TH, Kang DK, Kim KS, Yim H. Prognostic role of MRI enhancement features in patients with breast cancer: value of adjacent vessel sign and increased ipsilateral whole-breast vascularity. AJR Am J Roentgenol. 2012;199(4):921.PubMedCrossRef

36.

Ji YK, Kim SH, Yun JK, Kang BJ, An YY, Lee AW, et al. Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers? Magn Reson Imaging. 2015;33(1):72–80.CrossRef

37.

Sendur MAN, Aksoy S, Ozdemir NY, Yazici O, Zengin N, Altundag K. The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration. Curr Med Res Opin. 2014;186(12):1342–8.

38.

Kim TJ, Lee A, Choi YJ, Song BJ, Yim HW, Kang CS. Prognostic significance of high expression of ER-beta in surgically treated ER-positive breast cancer following endocrine therapy. J Breast Cancer. 2012;15(1):79–86.PubMedPubMedCentralCrossRef

39.

Buteau-Lozano H, Velasco G, Cristofari M, Balaguer P, Perrot-Applanat M. Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism. J Endocrinol. 2008;196(2):399.PubMedCrossRef

40.

Pelzer T, Jazbutyte V, Hu K, Segerer S, Nahrendorf M, Nordbeck P, et al. The estrogen receptor-alpha agonist 16 alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc Res. 2005;67(4):604–12.PubMedCrossRef

41.

Gagliato DM, Jardim DL, Marchesi MS, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016;7(39):64431.CrossRef

42.

Howell SJ, Wardley AM, Armstrong AC. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(24):1730–1.PubMedCrossRef

43.

Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S, Mochizuki T, et al. Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med. 2008;26(4):222–6.PubMedCrossRef

44.

Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res. 2003;9(4):1474–9.PubMed

45.

Kim SH, Cha ES, Kim HS, Kang BJ, Choi JJ, Ji HJ, et al. Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging. 2010;30(3):615–20.CrossRef

46.

Li TYT, Li L, Lu L, Zhuo Y, Lian J, Xiong Y, Kong D, Li K. Use of diffusion kurtosis imaging and quantitative dynamic contrast-enhanced MRI for the differentiation of breast tumors. J Magn Reson Imaging. 2018;48:1358–66.PubMedCrossRef

Title: Role of perfusion parameters on DCE-MRI and ADC values on DWMRI for invasive ductal carcinoma at 3.0 Tesla
Authors: Fei Liu
Mei Wang
Haige Li
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-018-1538-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Role of perfusion parameters on DCE-MRI and ADC values on DWMRI for invasive ductal carcinoma at 3.0 Tesla

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Laparoscopic intersphincteric resection with intraoperative radiotherapy using low-energy X-rays for locally advanced ultra-low rectal cancer

Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer

The diagnostic ureteroscopy before radical nephroureterectomy in upper urinary tract urothelial carcinoma is not associated with higher intravesical recurrence

Major vessel sealing in laparoscopic surgery for colorectal cancer: a single-center experience with 759 patients

Surgical treatment outcomes of patients with T1-T2 gastric cancer: does the age matter when excellent treatment results are expected?

Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer